BCAL Diagnostics Limited

A$0.07As of Sun 8 Nov 2026, 12:00 UTC
ASX:BDXHealthcare
Country Australia
PE (Fwd) •••
TSR 5Y CAGR (17.09%)
Div yield —
ROE (273.29%)
Diagnostics & Research
Beta (5Y) 0.72
PE TTM —
TSR TTM (29.47%)
Mkt cap A$24.70M
ROIC (60.16%)
SE Grade™
Value
Quality
Moat
Consensus
Reference
$0.0751
12.13%
(70.35%)
Hold 5|11|4|4|1
2Q26
3Q26
4Q26
1Q27
Earnings per share$
—
—
—
—
6.04%
8.96%
9.45%
12.81%
Revenue$M
1.365
1.366
1.401
1.374
4.62%
1.55%
5.07%
1.63%
Peers (US$16.97M)
Cap (US$)
PE
12.89M
99.65x
16.27M
—
Capital
TTM
5Y
10Y
Leveragex
1.915
(0.149)
(0.143)
EBIT/Intx
0.465
0.558
0.516
Own earn%
63.44
14.45
(4.61)
Sh yield%
45.69
25.55
23.69
Owners
Insiders/Inst%
7.42
50.45
Short interest%
1.94
SBC / revenue%
4.36
Record
10Y
Profitable years
10/10
Revenue growth years
10/10
EPS growth years
10/10
Dividend streakyrs
9
Op margin range%
22–27
$1 testx
0.1
Incr. ROIC%
−6